Reporting from 2021 ASCO Annual Meeting, Heather Wakelee comments on promising results from IMPOWER 010 testing atezolizumab vs best standard of care after adjuvant chemotherapy for stage II NSCLC with tumour expressing PD-L1. She also reports the overall survival results and subgroup analysis from the CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS G12C mutated NSCLC, as the drug has just been approved in the US.
This video was supported with an educational grant from Bayer, Daiichi Sankyo and Roche.
The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.